US officials reportedly withheld vaccine safety reports involving COVID-19 and shingles vaccines during ongoing federal policy changes.
- FDA officials reportedly withheld publication of COVID-19 and shingles vaccine safety reports
- Unpublished reports suggested serious vaccine-related adverse events were uncommon
- Broader US vaccine policy changes included funding reductions and revised recommendations
Officials at the U.S. Food and Drug Administration reportedly withheld or delayed publication of several reports related to COVID vaccine safety and the safety of the Shingrix shingles vaccine, according to coverage summarized by Center for Infectious Disease Research and Policy (CIDRAP) (1✔ ✔Trusted Source
CDC blocks publication of report showing COVID vaccine efficacy
Go to source
).
The unpublished reports reportedly suggested that serious vaccine-related adverse events were uncommon. However, because the reports were not formally published, the underlying data, methodology, and statistical analysis remain unavailable for independent scientific review.
The developments emerged during broader vaccine policy changes across US federal health agencies under Health Secretary Robert F. Kennedy Jr., who has publicly questioned vaccine safety policies and vaccine-related recommendations.
COVID Vaccine Safety Reports Were Reportedly Withdrawn
CIDRAP reported that two COVID-19 vaccine studies prepared by scientists from the Centers for Disease Control and Prevention were reportedly withdrawn in October 2025 after acceptance by medical journals.
The report also stated that FDA officials did not approve submission of abstracts related to safety evaluations of Shingrix, a shingles vaccine manufactured by GSK, for presentation at a drug safety conference.
Andrew Nixon, spokesperson for the US Department of Health and Human Services (HHS), stated that the reports were withdrawn because the authors drew “broad conclusions” that were “not supported by the underlying data”.
He also stated that the FDA acted to protect the integrity of its scientific review process and maintain standards for agency-associated research.
How the Vaccine Safety Reports Became Public
The FDA did not publish a formal press release or official website statement regarding the reported withdrawal of the vaccine safety reports.
According to CIDRAP, the information became public after comments from HHS spokesperson Andrew Nixon were shared with Reuters. Additional US media organizations later cited current and former federal officials familiar with the matter.
CIDRAP also reported that a CDC vaccine effectiveness report showing fewer emergency room visits and hospitalizations among vaccinated individuals was blocked from publication despite reportedly completing internal scientific review .
Broader Changes in US Vaccine Policy
The publication delays occurred during wider vaccine policy changes within US federal health agencies.
According to CIDRAP, these changes reportedly included reduced federal funding for mRNA vaccine development, revisions to some vaccine recommendations, and delays involving vaccine-related reports (1✔ ✔Trusted Source
CDC blocks publication of report showing COVID vaccine efficacy
Go to source).
Reports also stated that the HHS planned to reduce nearly $500 million in mRNA vaccine development funding, including cancellation of multiple BARDA-supported projects [1].
A CDC advisory panel also reportedly supported removal of the mercury-based preservative thimerosal from flu shots despite previous safety reviews conducted by public health agencies.
Why Publication of Vaccine Safety Data Matters
Public health experts generally consider publication of vaccine safety data important for scientific transparency and public confidence in immunization programs.
Vaccine monitoring systems commonly use observational studies, adverse-event reporting databases, and post-marketing surveillance to identify uncommon side effects that may not appear during initial clinical trials.
COVID-19 vaccines and shingles vaccines such as Shingrix previously underwent clinical testing and regulatory review before authorization in multiple countries.
Independent vaccine experts also note that withholding unpublished findings does not automatically invalidate the underlying research. At the same time, unpublished reports cannot undergo full scientific scrutiny until detailed methods and results become publicly available.
What the Debate Means for Public Trust in Vaccines
The reported withdrawal or delay of vaccine safety reports has intensified discussion in the United States regarding scientific transparency, vaccine oversight, and public trust in federal health agencies.
Because the reports remain unpublished, independent researchers cannot fully evaluate the evidence or conclusions. Health experts say continued access to peer-reviewed vaccine safety research remains important for clinicians, researchers, and the public when assessing vaccine risks and benefits.
Frequently Asked Questions
Q: Why were the COVID vaccine safety reports reportedly withdrawn?
A: HHS officials reportedly said the reports drew conclusions that were not fully supported by the underlying data.
Q: Did the FDA publicly announce withdrawal of the reports?
A: Reports indicate the FDA did not publish a formal public announcement or website statement regarding the withdrawals.
Q: What is the Shingrix vaccine used for?
A: Shingrix is a vaccine used to help prevent shingles, a painful rash caused by reactivation of the chickenpox virus.
Q: Were the vaccine safety reports independently reviewed?
A: Because the reports were not formally published, the underlying data and methods are not publicly available for independent scientific evaluation.
Q: Why is publication of vaccine safety data important?
A: Publishing vaccine safety data supports scientific transparency, independent review, and informed public health decision-making.
Reference:
- CDC blocks publication of report showing COVID vaccine efficacy – (https://www.cidrap.umn.edu/covid-19/cdc-blocks-publication-report-showing-covid-vaccine-efficacy)
Source-Medindia